Philip Rich, MD
Psychiatry · Reno, NVNPI 1235108804
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$901
- Takeda Pharmaceuticals U.S.A., Inc.$751
- Otsuka America Pharmaceutical, Inc.$689
- Almatica Pharma LLC$534
- Vanda Pharmaceuticals Inc.$466
- plus $1K from 20 others
What the payments were for
- Food & beverage$6,27799%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 135 | $1,490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $901 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $751 |
| Otsuka America Pharmaceutical, Inc. | 31 | $689 |
| Almatica Pharma LLC | 25 | $534 |
| Vanda Pharmaceuticals Inc. | 31 | $466 |
| Alkermes, Inc. | 10 | $251 |
| Corium, LLC | 16 | $251 |
| Lundbeck LLC | 8 | $131 |
| Johnson & Johnson | 6 | $123 |
| Supernus Pharmaceuticals, Inc. | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 6 | $99 |
| Eisai Inc. | 4 | $72 |
| Adlon Therapeutics L.p. | 4 | $70 |
| Brainsway USA Inc | 1 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Arbor Pharmaceuticals, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Indivior Inc. | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Neuronetics, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$120
How this compares
$6,324 in reported general payments places this provider in the 90th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 86 | $143,528 |
| VraylarCariprazine Hcl | 67 | $102,357 |
| RexultiBrexpiprazole | 44 | $75,735 |
| Wellbutrin XlBupropion Hcl | 13 | $26,738 |
| TrintellixVortioxetine Hydrobromide | 25 | $22,734 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 240 | $9,760 |
| VyvanseLisdexamfetamine Dimesylate | 24 | $9,033 |
| Quetiapine Fumarate | 248 | $8,341 |
| Lurasidone Hcl | 29 | $7,531 |
| Alprazolam | 686 | $6,783 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 152 | $6,684 |
| Carbamazepine | 182 | $5,353 |
| Ziprasidone Hcl | 54 | $5,057 |
| Doxepin Hcl | 275 | $4,972 |
| Atomoxetine Hcl | 72 | $4,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $901 | $143,52886 claims |
| AbbVieVraylar | $1,490 | $102,35767 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $689 | $75,73544 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $751 | $31,76749 claims |
| Johnson & JohnsonConcerta | $123 | $4,52211 claims |
| Corium, LLCAzstarys | $251 | $4,49711 claims |
| Almatica Pharma LLCSertraline Hcl | $534 | $2,263252 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Reno
- Philip MalinasReno$111K
- Brian KirkpatrickReno$18K
- Nickolas CulpepperReno$8K
- Meekile MasonReno$6K
- Geraldine SteinagelReno$4K
- Kathleen StollReno$3K
- Steven HolroydReno$3K
- Jayleen ChenReno$2K
- Thomas BittkerReno$2K
- Jelena KunovacLas Vegas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.